PR1 FDA Actions Against Health Economic Promotions, 2002-2011
نویسندگان
چکیده
منابع مشابه
FDA actions against health economic promotions, 2002-2011.
OBJECTIVE To investigate Food and Drug Administration (FDA) regulatory actions against drug companies' health economic promotions from 2002 through 2011 to understand how frequently and in what circumstances the agency has considered such promotions false or misleading. METHODS We reviewed all warning letters and notices of violation ("untitled letters") issued by the FDA's Division of Drug M...
متن کاملDischarge Against Medical Advice in the United States, 2002-2011.
OBJECTIVE To describe the national frequency, prevalence, and trends of discharge against medical advice (DAMA) among inpatient hospitalizations in the United States and identify differences across patient- and hospital-level characteristics, overall and in clinically distinct diagnostic subgroups. PATIENTS AND METHODS We conducted a retrospective, cross-sectional analysis of inpatient hospit...
متن کاملIntegrating Tobacco Cessation Quitlines Into Health Care: Massachusetts, 2002–2011
QuitWorks is a Massachusetts referral program that links health care organizations, providers, and patients to the state's tobacco cessation quitline and provides feedback reporting. Designed collaboratively with all major Massachusetts health plans, QuitWorks was launched in April 2002. In 2010, approximately 340 institutions and practices used QuitWorks. Between April 2002 and March 2011, app...
متن کاملBiologics clinical trials, research, and FDA actions.
Hopes raised, hopes dashed — the last half of 2012 has seen plenty of both. Enthusiasm over a bumper crop of U.S. Food and Drug Administration approvals has been tempered by a long list of phase 3 trial disappointments. Oncology agents led the way, starting with two drugs being studied for the treatment of non-small cell lung cancer. The addition of Eli Lilly’s pemetrexed (Alimta) to a regimen ...
متن کاملPelvic mesh complications in women before and after the 2011 FDA public health notification.
OBJECTIVES On July 13, 2011, the US Food and Drug Administration (FDA) released a public health notification with concerns regarding vaginal mesh for the treatment of pelvic organ prolapse. Our study compares the frequency and type of mesh complications related to female pelvic floor disorders presenting to our center before and after this notification. METHODS We performed a retrospective co...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2012
ISSN: 1098-3015
DOI: 10.1016/j.jval.2012.03.063